The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Official Title: Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Study ID: NCT06350825
Brief Summary: To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Detailed Description: To investigate the multimodality approaches for mHSPC
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Name: Lixin Hua, M.D.
Affiliation: The First Affiliated Hospital with Nanjing Medical University
Role: PRINCIPAL_INVESTIGATOR